Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

Show other versions (1)

Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people <55 years. Here, we report the saf...

Full description

Saved in:
Bibliographic Details
Main Authors: Pieter Pannus (Author), Stéphanie Depickère (Author), Delphine Kemlin (Author), Sarah Houben (Author), Kristof Y. Neven (Author), Leo Heyndrickx (Author), Johan Michiels (Author), Elisabeth Willems (Author), Stéphane De Craeye (Author), Antoine Francotte (Author), Félicie Chaumont (Author), Véronique Olislagers (Author), Alexandra Waegemans (Author), Mathieu Verbrugghe (Author), Marie-Noëlle Schmickler (Author), Steven Van Gucht (Author), Katelijne Dierick (Author), Arnaud Marchant (Author), Isabelle Desombere (Author), Kevin K. Ariën (Author), Maria E. Goossens (Author)
Format: Book
Published: Public Library of Science (PLoS), 2022-01-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items